Aug. 12, 2024 & 350mg.....
Cytodyn: "...announced today
Aug. 12, 2024 & 350mg.....
Cytodyn: "...announced today that it completed a meeting with the U.S. Food and Drug Administration (FDA) to... ** gain alignment on the rationale and proposed dosing **...for the Company’s Phase II study that will investigate the preliminary safety and activity of leronlimab in combination with trifluridine plus tipiracil (TAS-102) and bevacizumab in participants with CCR5+, microsatellite stable (MSS), relapsed or refractory metastatic colorectal cancer (mCRC).:
__
From Clinicals site:
The SUNLIGHT trial evaluated the combination of trifluridine/tipiracil (also known as Lonsurf) plus bevacizumab versus trifluridine/tipiracil alone in patients with metastatic colorectal cancer that had stopped responding to previous treatments. The trial demonstrated a statistically significant improvement in overall survival for the combination therapy compared to trifluridine/tipiracil alone. This combination is now considered a new standard of care for this patient population.
Improved Overall Survival:
The combination of trifluridine/tipiracil and bevacizumab resulted in a median overall survival of 10.8 months, compared to 7.5 months for trifluridine/tipiracil alone. This translates to a 39% reduction in the risk of death.
___
Our CRC trial mimicks SUNLIGHT with & without comparisons. I would guess the FDA & Cytodyn have agreed compiling data from 350mg to 700mg is once & for all, properly recognizing Leronlimab is far more than an Hiv blocker & not an immunesuppressior
Keep in mind, technically Cytodyn has never completed any special FDA designations from 2018 frwd...
Now Cytodyn agreeing with the new FDA,
DSMB can be trusted "middle man" with full FDA backing on that.
1 way squashing the...."past".
2nd -- 5 patients @ super fast pathway to 700mg = FDA show of good faith.
If trial Interim DSMB look reccomends stoppage & full approval, Cytodyn will have never needed to apply for AA or BTD....
All comes full circle with Cytodyn having praised FDA
7
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A $19,995 vacation is not selling a seat on a train; it is selling relief from planning, crowds and compromise. Great Rail Journeys is leaning hard into that proposition for 2027 with two additions to its premium Landmark Collection: a Europe-heavy Orient Express and Rhône cruise pairing, plus a South Africa itinerary built around safari, Victoria Falls and rail-flavored...
Continue Reading
Seven fewer injections every week is the real headline behind Novo Nordisk's latest FDA clearance, not some flashy efficacy leap. On November 20, 2026, the company said Sogroya, its once-weekly long-acting growth hormone, won approval for children aged 2.5 and older with growth failure associated with Turner syndrome. That matters because treatment can stretch over years,...
Continue Reading
A Huge Factory Claim Needs More Than Applause A magnet company just tossed a very large number onto Alabama's economic-development table. Niron Magnetics says it plans a $1.8 billion investment in the state that would create 700 jobs. That is not pocket change, not a ribbon-cutting trinket, and not the sort of announcement investors should breeze past between earnings...
Continue Reading
Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...
Continue Reading
Twenty-three million dollars can disappear fast in graduate health education, which is exactly why Rosalind Franklin University’s campaign result deserves more than a polite round of applause. The university’s five-year Empowering Scholars effort closed in June 2026 with $23,836,272 raised, clearing its $20 million target by roughly 19%. In a world where institutions...
Continue Reading
December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...
Continue Reading
Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...
Continue Reading
Aircraft shortages have a funny way of turning vague partnerships into very useful insurance policies. Flair Airlines, Phoenix Aviation Capital and Avia Solutions Group announced a Strategic Commercial Cooperation Agreement on Nov. 19, 2026, and the sensible reading is straightforward: the Canadian value carrier wants more ways to solve capacity and operational problems...
Continue Reading
Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...
Continue Reading
Three pairs of shoes are not a revolution, but they can expose whether a young brand has its footing. Align, established in 2025 by H.H. Brown, is rolling out the Wagner collection for Fall-Winter 2026 with a waterproof boot, a penny loafer and a lace-up oxford. That is a sensible little arsenal, not some overstuffed catalog dreamed up by a marketing committee that has...
Continue Reading
Top 5 Most Recently Viewed Articles
Growth Trajectory of the Global Microinsurance Market The microinsurance market is witnessing remarkable transformation as consumer demands shift towards financial inclusion, coupled with increasing awareness of the myriad advantages insurance provides. This positive trend is fueled by government initiatives aimed at regulation and expansion of microinsurance offerings,...
Continue Reading
Ormat Technologies Launches Secondary Stock Offering Ormat Technologies, Inc. (NYSE: ORA), renowned for its innovative geothermal and renewable energy solutions, recently announced an exciting development in the investment realm—the initiation of an underwritten secondary offering. This offering encompasses a total of 3,700,000 shares of common stock on behalf of ORIX...
Continue Reading
Insights from MongoDB Executive Share Transactions Cochran Hope F, a director at MongoDB, Inc. (NASDAQ: MDB), recently made notable moves with the company's Class A Common Stock, and these transactions were disclosed in the latest SEC filings. This activity has attracted attention from investors. In September, the director sold 1,174 shares at $224.38 each, which brought...
Continue Reading
Essential Guidance for Navigating Hurricane Travel Risks Hurricane season brings with it the potential for severe weather that can disrupt travel plans and lead to significant financial losses. As storms like Hurricane Helene have shown, the impact can be widespread, devastating homes and infrastructure, particularly in the southeastern regions. During these turbulent...
Continue Reading
Ascend Performance Materials Starts High-Purity Acrylonitrile Production Ascend Performance Materials has recently announced an exciting new phase in its production capabilities. The company is now producing high-purity acrylonitrile at its Chocolate Bayou facility. This advancement comes after the successful installation and commissioning of state-of-the-art purification...
Continue Reading